All viruses require genes from the cells they infect (host factors) to cause disease. These host factors are attractive drug targets as they cannot be mutated by the virus and thus cause less resistance. However, severe technical limitations have hitherto hampered systematic identification of these host factors. Haplogen's technology platform provides a rapid and reliable method to discover novel host factors against which new chemical or biological entities can be developed. Haplogen is currently pursuing targets to treat Influenza, the Common Cold, Dengue fever, Hanta/Lassa virus infections and Hepatitis C. All host factor drug targets are “first in class”.